Loading…
Eledon Pharmaceuticals, Inc. is projected to rise to $6.23 by 2027, a +62% move from its current price of $3.85. ELDN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $3.73 | $3.86 | $3.98 | +0.15% |
| Jul 15 | $3.69 | $3.86 | $4.04 | +0.29% |
| Jul 16 | $3.65 | $3.87 | $4.09 | +0.44% |
| Jul 17 | $3.63 | $3.87 | $4.13 | +0.58% |
| Jul 18 | $3.61 | $3.88 | $4.17 | +0.73% |
| Jul 19 | $3.59 | $3.88 | $4.21 | +0.88% |
| Jul 20 | $3.57 | $3.89 | $4.24 | +1.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.57 | $3.89 | $4.24 | +1.02% |
| Week 2 | $3.48 | $3.93 | $4.44 | +2.05% |
| Week 3 | $3.42 | $3.97 | $4.61 | +3.10% |
| Week 4 | $3.37 | $4.01 | $4.77 | +4.15% |
| Week 5 | $3.34 | $4.05 | $4.91 | +5.21% |
| Week 6 | $3.31 | $4.09 | $5.06 | +6.29% |
| Week 7 | $3.29 | $4.13 | $5.19 | +7.37% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Its lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. The company pursues its programs for the prevention of allograft rejection in kidney transplantation and xenotransplantation, and has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes.
The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
ELDN currently trades at $3.85 and has a market cap of $297.17M, ranking 3495 by market capitalization.
The stock shows a bullish longer‑term price outlook in the provided forecast, with the average price rising across years and a bullish sentiment prevailing after 2026. The year-by-year forecast begins with 2026 (avg $3.85) and extends through 2050 (avg $83.44), reflecting a multi‑year uptrend with progressively higher targets and sizable potential upside.
Key year‑by‑year anchors include 2027 (avg $6.23) and 2030 (avg $9.30), followed by a steep rise toward 2040 (avg $42.41) and 2050 (avg $83.44). The implied maximums in several years extend well above current levels, supporting a constructive, longer horizon view despite near‑term variance.
A major floor 35.1% below — a decisive break under it would weaken the trend.
The nearest floor, 11.4% below — buyers have tended to step in here.
The nearest ceiling, 9.4% above — a clean break opens room to run.
A major ceiling 20.1% above — clearing it would confirm fresh momentum.
Key ELDN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ELDN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.02 | Sell | $3.99 | Sell |
| MA 10 | $3.95 | Sell | $3.95 | Sell |
| MA 20 | $3.83 | Buy | $3.87 | Sell |
| MA 50 | $3.77 | Buy | $3.70 | Buy |
| MA 100 | $3.36 | Buy | $3.41 | Buy |
| MA 200 | $2.82 | Buy | $3.13 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.55 | Neutral |
| Stoch RSI (14) | 11.09 | Buy |
| CCI (20) | 8.53 | Neutral |
| Williams %R (14) | -64.29 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -2.53 | Sell |
| Bollinger %B (20,2) | 0.53 | Neutral |
| Stochastic %K (14) | 35.71 | Neutral |
| TRIX (15) | 0.28 | Buy |
| Awesome (5,34) | 0.25 | Buy |
| Ultimate (7,14,28) | 46.23 | Neutral |
| Momentum (10) | 0.20 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 4.10 | Sell |
| ADX (14) | 14.12 | Neutral |
| ATR (14) | 0.12 | Info |
The 30‑day technical picture places Eledon within a range of $3.10 to $4.77, indicating recent consolidation within a constructive band.
RSI14 is 50, with the 50‑day moving average at $3.77 and the 200‑day moving average at $2.82, framing a modestly constructive setup. On the chart, support sits at $3.41 and resistance at $4.21, aligning with a sentiment that remains BULLISH for the near term. The stock’s 30‑day range and volatility profile are consistent with an asset that can drift within a defined corridor before committing to a clearer trend.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.62 | $3.85 | $6.08 | 0% | Neutral | |
| $4.87 | $6.23 | $8.48 | +62% | Bullish | |
| $5.86 | $7.75 | $11.02 | +101% | Bullish | |
| $6.71 | $9.14 | $13.44 | +137% | Bullish | |
| $6.67 | $9.31 | $14.08 | +142% | Bullish | |
| $7.86 | $11.24 | $17.41 | +192% | Bullish | |
| $10.01 | $14.61 | $23.13 | +280% | Bullish | |
| $12.07 | $17.99 | $29.05 | +367% | Bullish | |
| $13.74 | $20.88 | $34.33 | +442% | Bullish | |
| $14.56 | $22.54 | $37.67 | +485% | Bullish | |
| $25.12 | $42.35 | $75.92 | +10.0x | Bullish | |
| $42.54 | $83.39 | $165.34 | +20.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.62 | $3.85 | $4.71 | +0.00% |
| August 2026 | $3.55 | $4.21 | $5.15 | +9.45% |
| September 2026 | $3.67 | $4.40 | $5.44 | +4.30% |
| October 2026 | $3.62 | $4.37 | $5.47 | -0.64% |
| November 2026 | $3.70 | $4.48 | $5.67 | +2.67% |
| December 2026 | $3.91 | $4.77 | $6.08 | +6.49% |
Click any year to see its month-by-month ELDN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Eledon Pharmaceuticals, Inc.'s 2026 outlook centres on $3.85, within a $1.62 to $6.08 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ELDN could reach as high as $8.48, with a base case around $6.23 and support toward $4.87 — roughly +62% from $3.85. Buyers look set to stay in control over this stretch.
Expect ELDN to range from $5.86 to $11.02 through 2028. The $7.75 average target implies a +101% move from current prices. That is up +24% on the projected 2027 average. Momentum favours further upside here.
The ELDN price prediction for 2029 points to an average of $9.14 (low $6.71, high $13.44) — a potential gain of +137% on today's $3.85. Buyers look set to stay in control over this stretch.
In 2030, ELDN is projected to trade between $6.67 and $14.08, averaging $9.31 — a potential gain of +142% from today's $3.85. That is up +2% on the projected 2029 average. Momentum favours further upside here.
Eledon Pharmaceuticals, Inc.'s 2031 outlook centres on $11.24, within a $7.86 to $17.41 range. That is up +21% on the projected 2030 average. That marks a +192% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ELDN could reach as high as $23.13, with a base case around $14.61 and support toward $10.01 — roughly +280% from $3.85. Momentum favours further upside here.
Expect ELDN to range from $12.07 to $29.05 through 2033. The $17.99 average target implies a +367% move from current prices. That is up +23% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ELDN price prediction for 2034 points to an average of $20.88 (low $13.74, high $34.33) — a potential gain of +442% on today's $3.85. Momentum favours further upside here.
In 2035, ELDN is projected to trade between $14.56 and $37.67, averaging $22.54 — a potential gain of +485% from today's $3.85. That is up +8% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Eledon Pharmaceuticals, Inc.'s 2040 outlook centres on $42.35, within a $25.12 to $75.92 range. That is up +88% on the projected 2035 average. That marks a +10.0x change versus current levels. Momentum favours further upside here.
By 2050, ELDN could reach as high as $165.34, with a base case around $83.39 and support toward $42.54 — roughly +20.7x from $3.85. Buyers look set to stay in control over this stretch.
Investing $1,000 in ELDN today (≈ 259.74026 ELDN) could be worth
$21,660.37
+$20,660.37 (+2066%) by 2050 · US Dollar
Based on the average projected ELDN price of $83.39 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ELDNwould be worth at today's price.
$1,000 invested in ELDN on Jul 10, 2025 (≈ 289.855068 ELDN) would be worth
$1,115.94
+$115.94 (+11.6%) today · 1.12× · US Dollar
Based on a ELDN entry price of $3.45 vs. today's $3.85.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.95 | $974.68 | -2.5% |
| 1 month ago | $3.46 | $1,112.72 | +11.3% |
| 3 months ago | $3.1 | $1,241.94 | +24.2% |
| 6 months ago | $1.91 | $2,015.71 | +101.6% |
| 1 year ago | $3.45 | $1,115.94 | +11.6% |
| All time (5.0y) ago | $7.53 | $511.29 | -48.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ELDN forecast.
Our base-case forecast reaches $7.70 around 2028.
Implied market cap at $7.70: $594.35M
The multi‑year forecast paints a persistent bullish trajectory, with meaningful upside over time. By 2030 the average price is projected at $9.30, with a bullish signal and a forecasted ROI of 141.6%. In the intervening years, the path remains positive, lifting to higher targets through 2035 and beyond.
The horizon extends to 2040, where the average forecast climbs to $42.41 and the ROI is projected at 1001.5%, underscoring a substantial long‑term appreciation possibility under the modeled trajectory. By 2050 the average forecast reaches $83.44 with an ROI of 2067.2% and a bullish sentiment, reflecting a strong growth scenario over the next couple of decades.
These figures are estimates, not guarantees, and carry inherent uncertainty. They illustrate a potential long‑term elevation in pricing and investor interest balanced by the usual risks of clinical stage biotechnology and regulatory development.
Tap a question to reveal the answer.
2030 avg price is $9.30, with a min of $6.66 and a max of $14.06, and a forecasted ROI of 141.6% with a BULLISH sentiment.
The forecast shows an average price of $9.30 in 2030 with an ROI of 141.6% and a BULLISH sentiment, suggesting potential upside over time (these are estimates, not guarantees).
Yes. The 2050 forecast includes a max price of $165.43, indicating the possibility of reaching and exceeding $100 by 2050 within the modeled horizon.
The current price is $3.85 and the market cap is $297.17M.
The 30‑day range is $3.10 to $4.77. RSI is 50, SMA50 is $3.77, SMA200 is $2.82, with support at $3.41 and resistance at $4.21; the sentiment is BULLISH and annualized volatility is 60%.
Eledon Pharmaceuticals, Inc. Community Discussion
0Share your Eledon Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.